There will still be a CR overhang. Either we proceed with a future (2nd) prophylactic or therapeutic study route, as the pack indicates, we will need more cash. I hope it is from a partnership instead of a dilution which would give us real validation and pathway to commercialisation - this would be easy to understand for the market and rerate us from this lowly MC.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)